HENLIUS (02696) Enters Cooperation Agreement with Auven Pharma for Commercialization of Fovistinib Citrate Capsules

Stock News

Dec 03

HENLIUS (02696) announced on December 3, 2025, that the company has signed a cooperation agreement with Auven Pharma. Under the agreement, Auven Pharma grants the group exclusive commercialization rights for the licensed product in specified regions and fields.

This agreement follows a memorandum of cooperation signed on August 7, 2025 (a transaction exempt under the minimum threshold of the Listing Rules), under which the group obtained exclusive commercialization rights for the licensed product in China during the interim period until the formal agreement was executed. The memorandum stipulated that both parties would enter into a definitive agreement once certain conditions were met.

The memorandum has now been superseded by the cooperation agreement and automatically terminated on December 3, 2025. The licensed product, Fovistinib Citrate Capsules, a CDK4/6 inhibitor, has been approved for the treatment of HR+/HER2– breast cancer.

The introduction of this product aligns with HENLIUS’s commercialization strategy in breast cancer and complements its existing pipeline of breast cancer therapies, creating commercial synergies. The addition of the licensed product will further enrich the company’s portfolio and leverage its established breast cancer commercialization team and resources to enhance future revenue growth.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1103203018"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1103203018\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1103203018?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-03 21:56","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103203018","market":"sg","top_or_hot":-1,"title":"HENLIUS (02696) Enters Cooperation Agreement with Auven Pharma for Commercialization of Fovistinib Citrate Capsules","media":"Stock News","content":"<p>HENLIUS (02696) announced on December 3, 2025, that the company has signed a cooperation agreement with Auven Pharma. Under the agreement, Auven Pharma grants the group exclusive commercialization rights for the licensed product in specified regions and fields.</p>\n<p>This agreement follows a memorandum of cooperation signed on August 7, 2025 (a transaction exempt under the minimum threshold of the Listing Rules), under which the group obtained exclusive commercialization rights for the licensed product in China during the interim period until the formal agreement was executed. The memorandum stipulated that both parties would enter into a definitive agreement once certain conditions were met.</p>\n<p>The memorandum has now been superseded by the cooperation agreement and automatically terminated on December 3, 2025. The licensed product, Fovistinib Citrate Capsules, a CDK4/6 inhibitor, has been approved for the treatment of HR+/HER2– breast cancer.</p>\n<p>The introduction of this product aligns with HENLIUS’s commercialization strategy in breast cancer and complements its existing pipeline of breast cancer therapies, creating commercial synergies. The addition of the licensed product will further enrich the company’s portfolio and leverage its established breast cancer commercialization team and resources to enhance future revenue growth.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HENLIUS (02696) Enters Cooperation Agreement with Auven Pharma for Commercialization of Fovistinib Citrate Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHENLIUS (02696) Enters Cooperation Agreement with Auven Pharma for Commercialization of Fovistinib Citrate Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-03 21:56</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>HENLIUS (02696) announced on December 3, 2025, that the company has signed a cooperation agreement with Auven Pharma. Under the agreement, Auven Pharma grants the group exclusive commercialization rights for the licensed product in specified regions and fields.</p>\n<p>This agreement follows a memorandum of cooperation signed on August 7, 2025 (a transaction exempt under the minimum threshold of the Listing Rules), under which the group obtained exclusive commercialization rights for the licensed product in China during the interim period until the formal agreement was executed. The memorandum stipulated that both parties would enter into a definitive agreement once certain conditions were met.</p>\n<p>The memorandum has now been superseded by the cooperation agreement and automatically terminated on December 3, 2025. The licensed product, Fovistinib Citrate Capsules, a CDK4/6 inhibitor, has been approved for the treatment of HR+/HER2– breast cancer.</p>\n<p>The introduction of this product aligns with HENLIUS’s commercialization strategy in breast cancer and complements its existing pipeline of breast cancer therapies, creating commercial synergies. The addition of the licensed product will further enrich the company’s portfolio and leverage its established breast cancer commercialization team and resources to enhance future revenue growth.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1103203018","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103203018","pubTimestamp":1764770181,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"HENLIUS (02696) announced on December 3, 2025, that the company has signed a cooperation agreement with Auven Pharma. Under the agreement, Auven Pharma grants the group exclusive commercialization...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02696":"复宏汉霖","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币"},"translate_title":"复宏汉霖(02696)与Auven Pharma就枸橼酸福维替尼胶囊商业化订立合作协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1},"content_text":"HENLIUS (02696) announced on December 3, 2025, that the company has signed a cooperation agreement with Auven Pharma. Under the agreement, Auven Pharma grants the group exclusive commercialization rights for the licensed product in specified regions and fields.\nThis agreement follows a memorandum of cooperation signed on August 7, 2025 (a transaction exempt under the minimum threshold of the Listing Rules), under which the group obtained exclusive commercialization rights for the licensed product in China during the interim period until the formal agreement was executed. The memorandum stipulated that both parties would enter into a definitive agreement once certain conditions were met.\nThe memorandum has now been superseded by the cooperation agreement and automatically terminated on December 3, 2025. The licensed product, Fovistinib Citrate Capsules, a CDK4/6 inhibitor, has been approved for the treatment of HR+/HER2– breast cancer.\nThe introduction of this product aligns with HENLIUS’s commercialization strategy in breast cancer and complements its existing pipeline of breast cancer therapies, creating commercial synergies. The addition of the licensed product will further enrich the company’s portfolio and leverage its established breast cancer commercialization team and resources to enhance future revenue growth.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}